Record growth for life science tech firm as MES adoption increases globally
Zenith Technologies surpasses the €20 million milestone for sales of its manufacturing execution system (MES) services.
Zenith Technologies provides MES and data historian deployment and support services to pharmaceutical and medical device manufacturers globally. The company has seen sales for this part of the business grow significantly over the last 5 years, with an average of over 35% year on year growth.
Commenting on the growth trend, James O’Brien, global MES business unit lead at Zenith Technologies, said: “MES has been the fastest growing segment of our offering and now represents almost a third of our business. Factors such as a greater regulatory focus on data integrity and customer demand for improved production performance have led to growing use of MES solutions within the pharmaceutical, biotech and medical device industries, which have traditionally been slow to adopt new technologies.
“The UK in particular is quickly becoming an MES centre of excellence, with MES sales representing 70% of our business in this market. Similarly, the US & Asia markets offer huge growth potential as the adoption of MES within the life science industry continues to grow across the globe.”
Zenith Technologies now works with nine of the top 10 pharmaceutical companies globally and during 2016 its team of engineers grew by almost 40% to over 700 employees.
To strengthen its ability to support customers in Europe, the US and Asia and accelerate further growth, the company has recently formed a number of strategic partnerships with MES technology providers, including Werum IT Solutions , AspenTech and LZ Lifescience. This will enable Zenith to support customers worldwide with on-site implementations of MES solutions designed to improve productivity, meet regulatory requirements during life science manufacturing and ultimately deliver vital medicines to patients as efficiently as possible.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance